Danaher Corporation (NYSE:DHR) is one of the best medical stocks to buy now. On September 22, BofA lowered the firm’s price target on Danaher Corporation (NYSE:DHR) to $220 from $230 while keeping a Buy rating on the shares. In contrast, the Life Diagnostics segment offers clinical instruments, devices, consumables, and other services for diagnosing and treating diseases. While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.